Article
Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC.
The New England journal of medicine - 24 Oct 2024
Cho Byoung C, Lu Shun, Felip Enriqueta, Spira Alexander I, Girard Nicolas, Lee Jong-Seok, Lee Se-Hoon, Ostapenko Yurii, Danchaivijitr Pongwut, Liu Baogang, Alip Adlinda, Korbenfeld Ernesto, Mourão Dias Josiane, Besse Benjamin, Lee Ki-Hyeong, Xiong Hailin, How Soon-Hin, Cheng Ying, Chang Gee-Chen, Yoshioka Hiroshige, Yang James C-H, Thomas Michael, Nguyen Danny, Ou Sai-Hong I, Mukhedkar Sanjay, Prabhash Kumar, D'Arcangelo Manolo, Alatorre-Alexander Jorge, Vázquez Limón Juan C, Alves Sara, Stroyakovskiy Daniil, Peregudova Marina, Şendur Mehmet A N, Yazici Ozan, Califano Raffaele, Gutiérrez Calderón Vanesa, de Marinis Filippo, Passaro Antonio, Kim Sang-We, Gadgeel Shirish M, Xie John, Sun Tao, Martinez Melissa, Ennis Mariah, Fennema Elizabeth, Daksh Mahesh, Millington Dawn, Leconte Isabelle, Iwasawa Ryota, Lorenzini Patricia, Baig Mahadi, Shah Sujay, Bauml Joshua M, Shreeve S Martin, Sethi Seema, Knoblauch Roland E, Hayashi Hidetoshi
Abstract excerpt
BACKGROUND: Amivantamab plus lazertinib (amivantamab-lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC). METHODS: In a phase 3, international, randomized trial, we assigned, in a 2:2:1 ratio, patients with previously untreated...
Read the complete abstract on PubMed